

Optimizing the Paradigm Shift Driven by CDK 4/6 Inhibition in Metastatic HR-Positive, HER2-Negative Breast Cancer

Resource	Address
Ingham M, Schwartz GK. Cell-cycle therapeutics come of age. <i>J Clin Oncol</i> . 2017;35:2949-2959.	https://ascopubs.org/doi/full/10.1200/JCO.2016.69.0032
Lynce F, et al. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. <i>Pharmacol Ther</i> . 2018;191:65-73.	https://www.sciencedirect.com/science/article/abs/pii/S0163725818301104
Finn RS, et al. Palbociclib and letrozole in advanced breast cancer. <i>N Engl J Med</i> . 2016;375:1925-1936.	https://www.nejm.org/doi/10.1056/NEJMoa1607303
Hortobagyi GN, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. <i>N Engl J Med</i> . 2016;375:1738-1748.	https://www.nejm.org/doi/full/10.1056/NEJMoa1609709
O'Shaughnessy J, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2-advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Res Treat</i> . 2018;168:127-134.	https://link.springer.com/article/10.1007%2Fs10549-017-4518-8
Rugo HS, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. <i>Breast Cancer Res Treat</i> . 2019;174:719-729.	https://link.springer.com/article/10.1007%2Fs10549-018-05125-4
Hortobagyi GN, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. <i>Ann Oncol</i> . 2018;29:1541-1547.	https://www.annalsofoncology.org/article/S0923-7534(19)32105-2/fulltext
Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. <i>Breast Cancer Res</i> . 2018;20:123.	https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-018-1050-7
Turner NC, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. <i>Ann Oncol</i> . 2018;29:669-680.	https://www.annalsofoncology.org/article/S0923-7534(19)35508-5/fulltext
Goetz MP, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. <i>J Clin Oncol</i> . 2017;35:3638-3646.	https://ascopubs.org/doi/full/10.1200/JCO.2017.75.6155
Johnston S, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>NPJ Breast Cancer</i> . 2019;5:5.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336880/
Tripathy D, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncol</i> . 2018;19:904-915.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext

<p>Im SA, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. <i>N Engl J Med.</i> 2019;381:307-316.</p>	<p>https://www.nejm.org/doi/full/10.1056/NEJMoa1903765</p>
<p>Turner NC, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. <i>N Engl J Med.</i> 2018;379:1926-1936.</p>	<p>https://www.nejm.org/doi/full/10.1056/NEJMoa1810527</p>
<p>Slamon DJ, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. <i>J Clin Oncol.</i> 2018;36:2465-2472.</p>	<p>https://ascopubs.org/doi/full/10.1200/JCO.2018.78.9909</p>
<p>Slamon DJ, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. <i>N Engl J Med.</i> 2020;382:514-524.</p>	<p>https://www.nejm.org/doi/full/10.1056/NEJMoa1911149</p>
<p>Sledge GW Jr, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. <i>J Clin Oncol.</i> 2017;35:2875-2884.</p>	<p>https://ascopubs.org/doi/full/10.1200/JCO.2017.73.7585</p>
<p>Sledge GW Jr, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2. <i>JAMA Oncol.</i> 2020;6:116-124.</p>	<p>https://jamanetwork.com/journals/jamaoncology/fullarticle/2752266</p>
<p>Cristofanilli M, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncol.</i> 2016;17:425-439.</p>	<p>https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00613-0/fulltext</p>